Follow
Meredith Mistark
Meredith Mistark
Boston Medical Center
Verified email at bmc.org
Title
Cited by
Cited by
Year
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
V Sanchorawala, S Sarosiek, A Schulman, M Mistark, ME Migre, R Cruz, ...
Blood, The Journal of the American Society of Hematology 135 (18), 1541-1547, 2020
1382020
Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study
V Sanchorawala, S Sarosiek, JM Sloan, D Brauneis, ME Migre, M Mistark, ...
Blood 130, 507, 2017
202017
Safety, tolerability and response rates of daratumumab in patients with relapsed light chain (AL) amyloidosis: results of a Phase II study
V Sanchorawala, S Sarosiek, JM Sloan, D Brauneis, ME Migre, M Mistark, ...
Blood 132, 2005, 2018
142018
The system can't perform the operation now. Try again later.
Articles 1–3